Product: VeriStrat
-
The Impact of Blood-Based Host Immune Profiling to Identify Aggressive Early-Stage NSCLC
-
Immunotherapy Alone or with Chemotherapy in Advanced NSCLC? Utility of Clinical Factors and Blood-Based Host Immune Profiling
-
Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy
-
Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis
-
Real World Performance of Blood Based Host Immune Profiling in First line Immunotherapy Treatment in Advanced Stage Non Small Cell Lung Cancer
-
Mass Spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy
-
The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy
-
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarkerstratified, randomised phase 3 trial
-
Real-World Performance of Blood-Based Proteomic Profiling in Immunotherapy Treatment in Advanced Stage NSCLC
-
Mass Spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy